{"id":"granix","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00005589","NCT00002791","NCT00006578","NCT05780879","NCT00003958","NCT01766934","NCT01329900","NCT00416598","NCT00058292","NCT00981799","NCT00002526","NCT00007982","NCT01572662","NCT07376460","NCT01110135","NCT00004089","NCT00004231","NCT00863434","NCT00906945","NCT00306111","NCT00030719","NCT02177695","NCT00003812","NCT01164475","NCT03922724","NCT00025259","NCT00003631","NCT01987596","NCT03136146","NCT00005959","NCT00003846","NCT00193973","NCT01105273","NCT00005796","NCT07186179","NCT00017355","NCT02221492","NCT00004899","NCT00025558","NCT04606082","NCT07107217","NCT01553214","NCT00001048","NCT00002831","NCT00004853","NCT00002675","NCT04959175","NCT01523678","NCT00880815","NCT01413178"],"aliases":["XM02 filgrastim"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Granix","companyId":"washington-university-school-of-medicine","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Washington University School of Medicine","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Granix","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00005589","phase":"Phase 3","title":"Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy","status":"COMPLETED","sponsor":"EBMT Solid Tumors Working Party","isPivotal":true,"enrollment":460,"indication":"Lymphoma","completionDate":"2013-04"},{"nctId":"NCT00002791","phase":"Phase 2","title":"A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","isPivotal":false,"enrollment":0,"indication":"Sarcoma","completionDate":"2013-11"},{"nctId":"NCT00006578","phase":"NA","title":"Evaluation of the Relationship Between Immunologic Recovery After Highly Active Antiretroviral Therapy and the Ability to Mobilize CD34+ Stem Cells Following G-CSF Administration","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":0,"indication":"HIV Infections","completionDate":""},{"nctId":"NCT05780879","phase":"Phase 2","title":"A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG","status":"SUSPENDED","sponsor":"University of Michigan Rogel Cancer Center","isPivotal":false,"enrollment":20,"indication":"Secondary Acute Myeloid Leukemia","completionDate":"2026-07"},{"nctId":"NCT00003958","phase":"Phase 3","title":"Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","isPivotal":true,"enrollment":702,"indication":"Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma","completionDate":""},{"nctId":"NCT01766934","phase":"N/A","title":"Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization","status":"COMPLETED","sponsor":"Sandoz","isPivotal":false,"enrollment":245,"indication":"Hematopoietic Stem Cell Mobilization","completionDate":"2024-08-29"},{"nctId":"NCT01329900","phase":"Phase 2","title":"Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":50,"indication":"Lymphoma","completionDate":"2019-07-21"},{"nctId":"NCT00416598","phase":"Phase 2","title":"Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":546,"indication":"Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes","completionDate":"2016-12-01"},{"nctId":"NCT00058292","phase":"Phase 1","title":"A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":44,"indication":"Lymphoma","completionDate":"2009-03"},{"nctId":"NCT00981799","phase":"Phase 1","title":"A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","isPivotal":false,"enrollment":23,"indication":"Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma","completionDate":"2016-07-18"},{"nctId":"NCT00002526","phase":"Phase 2","title":"Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma","status":"COMPLETED","sponsor":"Swiss Cancer Institute","isPivotal":false,"enrollment":20,"indication":"Ovarian Cancer, Sarcoma","completionDate":"1995-09"},{"nctId":"NCT00007982","phase":"Phase 2","title":"CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor","status":"COMPLETED","sponsor":"Herbert Irving Comprehensive Cancer Center","isPivotal":false,"enrollment":30,"indication":"Brain and Central Nervous System Tumors, Head and Neck Cancer","completionDate":"2008-05"},{"nctId":"NCT01572662","phase":"Phase 2","title":"Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":201,"indication":"Leukemia, Acute Myeloid Leukemia","completionDate":"2022-08-11"},{"nctId":"NCT07376460","phase":"N/A","title":"Biological and Proteomic Characterisation of Platelet-rich Plasma (PRP) Before and After Mobilisation of Haematopoietic Stem Cells in Peripheral Blood From Women With Low Ovarian Response (Low Respond","status":"NOT_YET_RECRUITING","sponsor":"Instituto Valenciano de Infertilidad, IVI Alicante","isPivotal":false,"enrollment":10,"indication":"Poor Ovarian Response, Ovarian Reactivation","completionDate":"2026-06"},{"nctId":"NCT01110135","phase":"Phase 2","title":"A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)","status":"COMPLETED","sponsor":"University of Washington","isPivotal":false,"enrollment":43,"indication":"Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma","completionDate":""},{"nctId":"NCT00004089","phase":"Phase 2","title":"A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":0,"indication":"Head and Neck Cancer","completionDate":"2002-04"},{"nctId":"NCT00004231","phase":"Phase 2","title":"Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Lymphoma","completionDate":"2006-08"},{"nctId":"NCT00863434","phase":"Phase 2","title":"A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Washington","isPivotal":false,"enrollment":2,"indication":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","completionDate":""},{"nctId":"NCT00906945","phase":"Phase 1","title":"Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":39,"indication":"Leukemia, Myeloid, Acute","completionDate":"2015-09"},{"nctId":"NCT00306111","phase":"Phase 2","title":"Pegfilgrastim Versus Filgrastim - Intraindividual Comparison of Quantity and Quality of Mobilized Peripheral Blood Stem Cells in Patients With Non Hodgkin-lymphoma","status":"COMPLETED","sponsor":"University Hospital Tuebingen","isPivotal":false,"enrollment":14,"indication":"Non-Hodgkin Lymphoma","completionDate":"2011-12"},{"nctId":"NCT00030719","phase":"Phase 3","title":"High Risk Neuroblastoma Study 1 Of Siop-Europe","status":"UNKNOWN","sponsor":"University of Leicester","isPivotal":true,"enrollment":175,"indication":"Neuroblastoma","completionDate":""},{"nctId":"NCT02177695","phase":"Phase 2","title":"A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":237,"indication":"Bladder Cancer","completionDate":"2022-12-01"},{"nctId":"NCT00003812","phase":"Phase 2","title":"Topotecan/Paclitaxel Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer: A Phase II Study","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","isPivotal":false,"enrollment":75,"indication":"Lung Cancer","completionDate":"2006-03"},{"nctId":"NCT01164475","phase":"Phase 4","title":"A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobili","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":61,"indication":"Non-Hodgkin's Lymphoma","completionDate":"2013-02"},{"nctId":"NCT03922724","phase":"Phase 2","title":"Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":330,"indication":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders","completionDate":"2030-10-31"},{"nctId":"NCT00025259","phase":"Phase 3","title":"A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","isPivotal":true,"enrollment":1734,"indication":"Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma","completionDate":""},{"nctId":"NCT00003631","phase":"Phase 2","title":"High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":118,"indication":"Lymphoma","completionDate":""},{"nctId":"NCT01987596","phase":"Phase 3","title":"Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","isPivotal":true,"enrollment":23,"indication":"Childhood Choroid Plexus Tumor, Childhood Medulloblastoma","completionDate":"2018-06"},{"nctId":"NCT03136146","phase":"Phase 2","title":"Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Ly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":42,"indication":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma","completionDate":"2027-08-01"},{"nctId":"NCT00005959","phase":"Phase 2","title":"Phase II Trial of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated Intermediate or High Grade Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Amgen","isPivotal":false,"enrollment":0,"indication":"Lymphoma","completionDate":""},{"nctId":"NCT00003846","phase":"Phase 2","title":"Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support","status":"COMPLETED","sponsor":"Children's Oncology Group","isPivotal":false,"enrollment":25,"indication":"Brain and Central Nervous System Tumors, Neuroblastoma","completionDate":"2007-03"},{"nctId":"NCT00193973","phase":"Phase 2","title":"A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","isPivotal":false,"enrollment":20,"indication":"Primary Central Nervous System Lymphoma","completionDate":"2013-08"},{"nctId":"NCT01105273","phase":"Phase 1","title":"HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia After Conditioning of Fludarabine, Cyclophosphamide and Antithymocyte Globul","status":"COMPLETED","sponsor":"Asan Medical Center","isPivotal":false,"enrollment":12,"indication":"Aplastic Anemia","completionDate":"2012-07"},{"nctId":"NCT00005796","phase":"Phase 1","title":"A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Pe","status":"COMPLETED","sponsor":"Indiana University","isPivotal":false,"enrollment":10,"indication":"Bone Marrow Suppression, Brain and Central Nervous System Tumors","completionDate":"2011-12"},{"nctId":"NCT07186179","phase":"N/A","title":"Mobilization of CD34+ Peripheral Blood Stem Cells With Filgrastim (Granulocyte-colony Stimulating Factor) and Plerixafor From Patients With Diamond Blackfan Anemia Syndrome","status":"RECRUITING","sponsor":"Northwell Health","isPivotal":false,"enrollment":10,"indication":"Diamond Blackfan Anemia","completionDate":"2027-04-01"},{"nctId":"NCT00017355","phase":"Phase 1","title":"Mature Dendritic Cell Immunotherapy Of Metastatic Melanoma- A Phase I Trial","status":"UNKNOWN","sponsor":"Baylor Health Care System","isPivotal":false,"enrollment":0,"indication":"Melanoma (Skin)","completionDate":""},{"nctId":"NCT02221492","phase":"Phase 2","title":"A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral ","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":32,"indication":"Lymphoma","completionDate":"2016-03"},{"nctId":"NCT00004899","phase":"Phase 2","title":"Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Leukemia, Myelodysplastic Syndromes","completionDate":"2004-08"},{"nctId":"NCT00025558","phase":"Phase 1","title":"Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease","status":"COMPLETED","sponsor":"NYU Langone Health","isPivotal":false,"enrollment":0,"indication":"Brain and Central Nervous System Tumors","completionDate":""},{"nctId":"NCT04606082","phase":"NA","title":"Intra Uterine Injection of Human Chorionic Gonadotropin Versus Granulocyte Colony Stimulating Factor at Ovum Pick up Day Significantly Increase Implantation Rate and Pregnancy Rate in Intra Cytoplasmi","status":"UNKNOWN","sponsor":"Al-Azhar University","isPivotal":false,"enrollment":200,"indication":"Fertility Disorders","completionDate":"2021-01-10"},{"nctId":"NCT07107217","phase":"Phase 2","title":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","isPivotal":false,"enrollment":40,"indication":"Breast Cancer","completionDate":"2027-12"},{"nctId":"NCT01553214","phase":"Phase 4","title":"Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","isPivotal":false,"enrollment":1000,"indication":"Allogeneic Granulocyte Donation","completionDate":"2032-01-01"},{"nctId":"NCT00001048","phase":"Phase 2","title":"A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":90,"indication":"HIV Infections, Leukoencephalopathy, Progressive Multifocal","completionDate":"1997-04"},{"nctId":"NCT00002831","phase":"Phase 1","title":"A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":24,"indication":"Leukemia","completionDate":"2002-12-31"},{"nctId":"NCT00004853","phase":"Phase 1","title":"A Randomized Trial of Filgrastim-SD/01 vs. Filgrastim in Newly Diagnosed Children and Young Adults With Sarcoma Treated With Dose-Intensive Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":34,"indication":"Ewing's Sarcoma, Rhabdomyosarcoma","completionDate":"2009-05-20"},{"nctId":"NCT00002675","phase":"Phase 2","title":"A TRIAL OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH INTRAOCULAR RETINOBLASTOMA","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":50,"indication":"Retinoblastoma","completionDate":"2001-01"},{"nctId":"NCT04959175","phase":"Phase 1","title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":320,"indication":"Hematologic Neoplasms","completionDate":"2027-04-30"},{"nctId":"NCT01523678","phase":"Phase 2","title":"Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers","status":"COMPLETED","sponsor":"Belgian Gynaecological Oncology Group","isPivotal":false,"enrollment":108,"indication":"Ovarian Cancer, Endometrial Cancer","completionDate":"2018-08-14"},{"nctId":"NCT00880815","phase":"Phase 1","title":"Fludarabine, Bendamustine, and Rituximab (FBR) Non-Myeloablative Allogeneic Conditioning for Patients With Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":60,"indication":"CD20 Positive, Chronic Lymphocytic Leukemia","completionDate":"2019-05-28"},{"nctId":"NCT01413178","phase":"Phase 3","title":"A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":true,"enrollment":205,"indication":"Myeloma","completionDate":"2019-03-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}